-

Announcing New Fourier 80 Benchtop FT-NMR Capabilities for Pharmaceutical and Food Analysis Markets

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announces new capabilities for its benchtop Fourier transform (FT) nuclear magnetic resonance (NMR) spectrometer, the Fourier 80, which does not require special lab infrastructure or cryogens, and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes. A new adjustable temperature option increases experimental flexibility, while new solutions for pharma and food analysis provide improved synthesis and process control, bringing NMR capabilities to more research and analytical laboratories.

The enhanced Fourier 80 now features an Adjustable Temperature (AT) option, expanding its range of applications by enabling sample analysis from 25°C up to 60°C, all compatible with the optional Fourier 80 PAL sample changer.

The new Fourier 80 reaction monitoring solution RxnLab™ for chemical and pharmaceutical labs features temperature-controlled reaction paths to minimize heat loss, optimize process control, and monitor reaction products with the new Fourier 80 flow accessory. Running InsightMR software, the RxnLab brings benchtop FT-NMR to bio- and chemical production with push-button operation for non-NMR experts. For non-flow measurements, the Fourier RxnLab can also use standard 5 mm NMR tubes. The new Fourier 80 GxP Readiness Kit allows full GxP compliance for development and manufacturing labs with 21 CFR part 11 compliance.

“We love the Fourier 80, it has been working 24/7 since it arrived,” states Professor Andre Simpson from the University of Toronto. “What sets it apart is its flexibility to run experiments from our high field NMR systems, including all the pulse programs we have written ourselves. The Fourier 80 revolutionizes what we can do at low field and truly establishes it as a powerful research tool.”

A new Fourier 80 food analysis solution, called NMR Olive Oil-Profiling™ 1.0, delivers authenticity and quality analysis of olive oil, one of the most adulterated food products worldwide. The new Olive Oil-Profiling 1.0 solution is suitable for olive oil bottlers, olive oil testing laboratories, and satellite laboratories. Its companion high-field 400 MHz NMR FoodScreener supports private testing and governmental laboratories in the analysis of multiple or complex food matrices.

Dr. Venita Decker, Bruker’s Product Manager Compact NMR, stated: “These new Fourier 80 capabilities and solutions push the boundaries of benchtop FT-NMR. With the Adjustable Temperature option, analytical chemists can now measure samples, e.g. at 25°C, or 37°C one day, and polymers at 60°C the next. This is particularly useful for reaction monitoring in chemical and pharmaceutical research and QC.”

For more information, visit our Fourier 80 website.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Customer Contact:
Dr. Venita Decker
Product Manager Compact NMR (TD/FT)
Bruker BioSpin Group
E: compact.ftnmr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Customer Contact:
Dr. Venita Decker
Product Manager Compact NMR (TD/FT)
Bruker BioSpin Group
E: compact.ftnmr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom